Payload Information

General Information of This Payload
Payload ID
PAY0RUSHL
Name
Exatecan derivative (HS-9265)
Target(s) DNA topoisomerase 1 (TOP1)
 Target Info 
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
HS-20093 [Phase 3]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05276609  Phase Status Phase 1
Clinical Description
ARTEMIS-001: A phase 1, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and efficacy of multiple doses of intravenous administration of HS-20093 in patients with locally advanced or metastatic solid tumors who have progressed following prior therapy.
References
Ref 1 ARTEMIS-001: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Intravenous Administration of HS-20093 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy, NCT05276609